Skip to content

Bioelectrical Impedance Vector Analysis in Cirrhotic Patients

Malnutrition Assessed Through Bioelectrical Impedance Vector Analysis is Related to Poor Prognosis in Cirrhosis

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01603953
Acronym
BIVA
Enrollment
250
Registered
2012-05-23
Start date
2009-01-31
Completion date
2014-05-31
Last updated
2014-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cirrhosis, Hepatic Encephalopathy

Brief summary

Protein-energy malnutrition and muscle wasting are a common finding among patients with liver cirrhosis. Its prevalence may range from 50-90% depending on the methods used for nutritional assessment. Even stable cirrhotic patients referred as Child A have muscle depletion and the majority of patients classified as Child C have significant depletion. Malnutrition has been shown to be related to several complications of cirrhosis Despite the importance of nutritional status in patient's outcome, there is no gold standard for nutritional assessment. Traditional techniques used in healthy subjects to assess nutritional status cannot be used in cirrhotic patients due especially to ascites and peripheral edema, and altered rates of biochemical markers due to liver failure. Bioelectrical impedance vector analysis has emerged as a useful method to assess body composition and nutritional status especially in patients at the extremes of body weight (fluid overload, excess of adipose tissue, etc.). The aim of this study is to evaluate whether malnutrition assessed by bioelectrical impedance vector analysis is related to the development of hepatic encephalopathy

Interventions

None listed

Sponsors

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Diagnose of cirrhosis. * Ambulatory patients

Exclusion criteria

* Personal history of surgery in the last four weeks * Thyroid disorders without replacement therapy * Pregnancy * Active alcoholism with alcohol ingest in the previous 6 months. * Acute or chronic renal failure * Hepatic or renal transplant

Design outcomes

Primary

MeasureTime frameDescription
Hepatic encephalopathy6, 12, 24, 36 and 48 monthsAssessed by west Haven criteria

Secondary

MeasureTime frame
Ascites6, 12, 24, 36 and 48 months

Countries

Mexico

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026